Effect of interleukin 6 on the hepatic metabolism of itraconazole and its metabolite hydroxyitraconazole using primary human hepatocytes

Pharmacology

Volumn 67, Issue 4, 2003, Pages 195-201

  Gubbins, Paul O ^a   Melchert, Russell B ^a   McConnell, Scott A ^a   Franks, Amy M ^a   Penzak, Scott R ^b   Gurley, Bill J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Drug metabolism; Interleukin 6; Itraconazole

Indexed keywords

CELL PROTEIN; CIMETIDINE; CYTOCHROME P450 3A4; HYDROXYITRACONAZOLE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; ITRACONAZOLE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; LIVER CELL; LIVER CELL CULTURE; LIVER METABOLISM; MALE; MEASUREMENT; PRIORITY JOURNAL; PROTEIN INTERACTION;

ADULT; CELLS, CULTURED; CIMETIDINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HEPATOCYTES; HUMANS; INTERLEUKIN-6; ITRACONAZOLE; LIVER; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6;

EID: 0346035743     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068401     Document Type: Article

References (23)

1. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, Turlin B, Beaune P, Guillouzo A: Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993;44:707-715.
2. Shedlofsky SI, Israel BC, McClain CJ, Hill DB, Blouin RA: Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 1994;94:2209-2214.
3. Chen YL, Le Vraux V, Leneveu A, Dreyfus F, Stheneur A, Florentin I, De Sousa M, Giroud JP, Flouvat B, Chauvelot-Moachon L: Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 1994;55:649-660.
4. Gurley BJ, Barone GW, Yamashita K, Polston S, Estes M, Harden A: Extrahepatic ischemia-reperfusion injury reduces hepatic oxidative drug metabolism as determined by serial antipyrine clearance. Pharm Res 1997;14:67-71.
5. Gubbins PO, Gurley BJ, Arnold E, Tricot G, Vesole D, Bradsher RW, McDonnell R, Zermatten SA: A study to determine the pharmacokinetics of itraconazole and its metabolite, hydroxyitraconazole, in allogeneic bone marrow transplant recipients (abstract 971); in: Programs and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco 1995. Washington, American Society of Microbiology, 1995.
6. Heykants J, Michiels M, Meuldermans W, Monbaliu J, Lavrijsen K, Van Peer A, Levron JC, Woestenborghs R, Cauwenbergh G: The phamacokinetics of itraconazole in animals and man: An overview; in Fomtling RA (ed): Recent Trends in the Discovery, Development and Evolution of Antifungal Agents. Barcelona, Prous, 1987, pp 223-249.
7. Willems L, van der Geest R, de Beule K: Itraconazole oral solution and intravenous formulations: A review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2001;26:159-169.
8. Kishimoto T: The biology of interleukin-6. Blood 1989;74:1-10.
9. Kishimoto T, Akira S, Taga T: IL-6 receptor and mechanism of signal transduction. Int J Immunopharmacol 1992;14:431-438.
10. Bataille R, Jourdan M, Zhang XG, Klein B: Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84:2008-2011.
11. Wierzbowska A, Urbanska-Rys H, Robak T: Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. Br J Haematol 1999;105:412-419.
12. Fischer CP, Bode BP, Takahashi K, Tanabe KK, Souba WW: Glucocorticoid-dependent induction of interleukin-6 receptor expression in human hepatocytes facilitates interleukin-6 stimulation of amino acid transport. Ann Surg 1996;223:610-619.
13. Muntané-Relat J, Ourlin JC, Domergue J, Maurel P: Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 1995;22:1143-1153.
14. Rabinowitz J, Petros WP, Stuart AR, Peters WP: Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support. Blood 1993;81:2452-2459.
15. Gubbins PO, Gurley BJ, Bowman JL: Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum. J Pharm Biomed Anal 1998;16:1005-1012.
16. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
17. Prentice AG, Donnelly P: Oral antifungals as prophylaxis in haematological malignancy. Blood Rev 2001;15:1-8.
18. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, Woestenborghs R, Van Cutsem J, Cauwenbergh G: The clinical pharmacokinetics of itraconazole: An overview. Mycoses 1989;32(suppl 1):67-87.
19. Ducharme MP, Slaughter RL, Warbasse LH, Chandrasekar PH, Van de Velde V, Mannens G, Edwards DJ: Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 1995;58:617-624.
20. IIB in cultured rat hepatocytes. Biochem Biophys Res Commun 1991;178:1049-1055.
21. 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998;87:1322-1330.
22. Morel F, Beaune PH, Ratanasavanh D, Flinois JP, Yang CS, Guengerich FP, Guillouzo A: Expression of cytochrome P-450 enzymes in cultured human hepatocytes. Eur J Biochem 1990;191:437-444.
23. Thummel KE, Wilkinson GR: In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430.